MyHep

MyHep 400 mg (Sofosbuvir) belongs to the class of direct-acting antiviral (DAA) drugs used against Hepatitis C viral (HCV) infection. It is specified in patients suffering from HCV genotype 1, 2, 3 or 4.

MyHep 400 mg (Sofosbuvir) is recommended in combination with other anti-HCV agents (ribavirin and pegylated interferon). Sofosbuvir in combination with these agents imparts advantages like,

• Damages associated with the liver is reduced
• Occurrence of liver cancer is slowed down (hepatocellular carcinoma)
• Increased quality of life of patients

Sofosbuvir acts by specifically inhibiting a distinct type of protein (non-structural protein 5B (NS5B) RNA polymerase], preventing further multiplication (RNA replication) of viral cells. With this action, sofosbuvir can decrease viral load in the system to gain a sustained virologic response (SVR).

Administration of MyHep 400 mg (Sofosbuvir):

Hepcinat 400 mg (Sofosbuvir) is administered orally once in a form of 400 mg dose daily for 12 to 24 weeks. It can be taken with or without food. Besides, either ribavirin alone or ribavirin plus pegylated interferon is also recommended.

Dosage regimen for MyHep 400 mg (Sofosbuvir):

Type 1 or 4: MyHep 400 mg (Sofosbuvir) + ribavirin and pegylated interferon for 12 weeks

Type 2: MyHep 400 mg (Sofosbuvir) + ribavirin for 12 weeks

Type 3: My Hep 400 mg (Sofosbuvir) + ribavirin for 24 weeks

Special conditions:

Note: Both pros and cons should be taken into consideration before increasing the duration of treatment.

Once swallowed, sofosbuvir is absorbed (bio-available) in between 30 mins to 2 hours. It has a pertinent binding affinity (61-65%) with viral cells and is broadly metabolized in the liver. After its activities, more than 50% of the drug is excreted from the body in between 40 minutes to 27 hours.

When should MyHep 400 (Sofosbuvir) be avoided or used cautiously?

• If patients are suffering from or had a history of Hepatitis B viral infection before taking sofosbuvir
• If patients had a liver transplant before the initiation of dosage
• If patients have complications in the liver other than HCV infection
• If patients are suffering from heart problems, kidney disease or undergoing dialysis, HIV infection, or other severe medical condition
• If patients are taking any sort of non-prescribed or prescribed drugs, herbal medicines, or dietary supplementary
• Avoid having intercourse (sex) without condoms, HCV may spread to your partner if you are under treatment
• If patients are pregnant and planning to breastfeed

Side-effects of Hepcinat 400 mg (Sofosbuvir):

Sofosbuvir has a reasonable safety profile with minimal side-effects. Due to its safety profile, it has a therapeutic advantage over other anti-HCV agents with the absence of low red blood cell (RBC) count (anemia) and neuropsychiatric effects.

Serious side-effects: Slow heart rate (bradycardia)

Side-effects in combination with ribavirin:

• Headache
• Tiredness (Fatigue)

Side-effects in combination with ribavirin and pegylated interferon:

• Lack of sleep (Insomnia)
• Nausea
• Tiredness (Fatigue)
• Headache

Uncommon side-effects: 

• Low consumption of diet
• Pain in the muscles (Myalgia)
• Physical weakness (Asthenia)
• Skin itchiness (Pruritis)
• Diarrhea
• Severe rashes on the skin

Note: These are not all possible side-effects of MyHep 400 mg (Sofosbuvir), please ask your doctor for more information regarding the same.